Lipocine (NASDAQ:LPCN) Chief Executive Officer Dr. Mahesh Patel said the biopharmaceutical company is pursuing regulatory discussions and preparing for a potential validation trial after its Phase 3 study of LPCN 1154 in postpartum depression missed its primary endpoint.
Speaking during an Alliance Global Partners fireside chat, Patel said Lipocine was “disappointed” by the top-line result but believes the trial showed signs of rapid efficacy and a differentiated safety profile. LPCN 1154 is being developed as an oral treatment for postpartum depression, using Lipocine’s proprietary drug delivery technology.
CEO Points to Outlier Site in Phase 3 Trial
Patel said Lipocine identified one trial site that he described as an “epidemiologic outlier” and materially different from the rest of the study population. According to Patel, that site accounted for about one-third of the trial and enrolled patients five times faster than the other 14 sites.
He said 78% of patients from that site were “de novo” postpartum depression patients, meaning they had no history of postpartum depression or another psychiatric illness. Patel said that differed from typical postpartum depression epidemiology, where de novo patients are generally less than 20%, and contrasted with the other sites, which he said were more consistent with real-world patient characteristics.
Patel also said seven of 11 patients on active treatment at that site had no detectable drug levels, suggesting a possible compliance issue. He added that the site showed a 92% placebo response and an 83% remission rate, which he characterized as “unheard of.”
Subgroup Data Showed Rapid Response, Patel Says
Patel said that when the outlier site was excluded, the data showed statistically significant results at all measured time points, including as early as 12 hours. He said the treatment effect was greater than minus five at each time point and reached minus 7.1 at 12 hours in that subgroup analysis.
He also said Lipocine evaluated another subgroup excluding de novo patients and saw a consistent trend across outcomes including HAM-D, remission and response measures. Patel said the findings, if confirmed, could support LPCN 1154 as a rapid-acting treatment for postpartum depression.
“If the subgroup results are verified, we believe that the results are very consistent and it all points toward the fastest relief for postpartum depression as early as 12 hours,” Patel said.
Safety Profile Compared With Approved Treatment
Patel contrasted LPCN 1154’s safety profile with ZURZUVAE, which he described as the only approved postpartum depression product currently on the market. He said IV brexanolone has been withdrawn for commercial reasons.
According to Patel, Lipocine observed no adverse events occurring in more than 5% of LPCN 1154-treated participants. He said somnolence and sedation were seen in 4% of patients, compared with 19% to 36% in ZURZUVAE studies cited by Patel. He also said dizziness occurred in 4% of LPCN 1154 patients, compared with 13% to 18% for ZURZUVAE in the comparisons he presented.
Patel said LPCN 1154 also had no treatment discontinuations and no dose reductions due to sedation or somnolence. He described the drug’s proposed 48-hour treatment duration as a differentiator versus ZURZUVAE’s two-week regimen.
Regulatory Path and Potential New Trial
Patel said Lipocine has applied for breakthrough therapy and fast track designations based on the subgroup analysis. He said the company has also requested a guidance meeting with the U.S. Food and Drug Administration to discuss the Phase 3 data, including whether the agency would consider excluding the outlier site when assessing efficacy.
At the same time, Patel said Lipocine is designing a protocol for a new study in case one is required. He said the company is working on a “de-risking strategy” that would seek to avoid similar site-related issues.
Asked whether Lipocine has the balance sheet to run another trial, Patel said the company reported about $25 million in cash in its most recent public earnings release. He said the burn rate, even with a potential validation trial, should be about $1 million per month, similar to last year’s rate. Patel said the company could have interim results in the first quarter of next year if a new trial proceeds, with approximately $14 million to $15 million remaining at that time.
The Alliance Global Partners analyst said he expects Lipocine may need to run another trial, while noting that the company’s interpretation of the outlier site warrants further attention. Patel said Lipocine is preparing for both possibilities: an FDA path that accepts the company’s exclusion argument or a new validation study.
About Lipocine (NASDAQ:LPCN)
Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.
The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.
-logo-1200x675.jpg){kind=logo}
